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Protein degradation by the ubiquitin-proteasome
system is central to cell homeostasis and survival.
Defects in this process are associated with diseases
such as cancer and neurodegenerative disorders.
The 26S proteasome is a large protease complex
that degrades ubiquitinated proteins. Here, we
show that ADP-ribosylation promotes 26S protea-
some activity in both Drosophila and human cells.
We identify the ADP-ribosyltransferase tankyrase
(TNKS) and the 19S assembly chaperones dp27
and dS5b as direct binding partners of the protea-
some regulator PI31. TNKS-mediated ADP-ribosyla-
tion of PI31 drastically reduces its affinity for 20S
proteasome a subunits to relieve 20S repression by
PI31. Additionally, PI31 modification increases bind-
ing to and sequestration of dp27 and dS5b from 19S
regulatory particles, promoting 26S assembly. Inhibi-
tion of TNKS by either RNAi or a small-molecule
inhibitor, XAV939, blocks this process to reduce
26S assembly. These results unravel a mechanism
of proteasome regulation that can be targeted with
existing small-molecule inhibitors.
INTRODUCTION
Selective protein degradation plays a central role for the removal
of misfolded and potentially toxic proteins, the control of cell-
cycle progression, the regulation of gene expression, and
changes in cell size and morphology (Baumeister et al., 1998;
Demartino and Gillette, 2007; Finley, 2009; Glickman and Cie-
chanover, 2002; Hershko, 2005; Hershko and Ciechanover,
1998; Murata et al., 2009; Tanaka et al., 2012). Moreover,
abnormal protein degradation is associated with a wide range
of human diseases, such as cancer, muscle-wasting diseases,
and neurodegenerative disorders (Glickman and Ciechanover,
2002; Goldberg, 2007; Hershko and Ciechanover, 1998). The
selective degradation of most intracellular proteins is carried
out by the ubiquitin-proteasome system (UPS) (Finley, 2009;
Glickman and Ciechanover, 2002; Hershko and Ciechanover,
1998; Varshavsky, 2012). Proteins tagged with polyubiquitin
chains are hydrolyzed into small peptides by the 26S protea-614 Cell 153, 614–627, April 25, 2013 ª2013 Elsevier Inc.some in an energy-dependent manner (Baumeister et al., 1998;
Besche et al., 2009b; Demartino and Gillette, 2007; Finley,
2009; Tanaka et al., 2012; Tomko and Hochstrasser, 2011).
The 26S proteasome is a large protease complex composed
of a catalytic 20S subunit (also known as 20S core particle)
and a 19S regulatory particle that caps one or both ends of
the 20S proteasome (Baumeister et al., 1998; Besche et al.,
2009b; Demartino and Gillette, 2007; Finley, 2009; Lander
et al., 2012; Lasker et al., 2012; Murata et al., 2009; Tanaka
et al., 2012; Tomko and Hochstrasser, 2011). The assembly
and activity of the 26S proteasome is tightly regulated by a large
number of loosely associated proteins that function as regulators
or cofactors (Besche et al., 2009b; Finley, 2009; Tanaka et al.,
2012; Tomko and Hochstrasser, 2011). One such factor is
PI31, an evolutionarily conserved regulator of proteasome activ-
ity (Bader et al., 2011; Chu-Ping et al., 1992; McCutchen-Malo-
ney et al., 2000; Zaiss et al., 1999). PI31 was initially identified
on the basis of its ability to inhibit 20S proteasome activity
in vitro (Chu-Ping et al., 1992; McCutchen-Maloney et al.,
2000; Zaiss et al., 1999). However, PI31 can also activate the
26S proteasome in vitro, and mutational inactivation of the cor-
responding gene in Drosophila causes lethality-reduced protea-
some activity and defects in protein degradation in vivo (Bader
et al., 2011). Therefore, PI31 serves a crucial physiological func-
tion as an activator of 26S proteasome activity. The C terminus of
PI31 contains a functionally important HbYX (hydrophobic resi-
due-tyrosine-any amino acid) motif, which is commonly found
in modulators of proteasome activity, such as Rpt base subunits
of the 19S regulatory particle (Gillette et al., 2008; Rabl et al.,
2008; Smith et al., 2007). This suggests that PI31 can bind to
the 20S particle via its HbYX motif, and this may cause inhibition
by hindering substrate access to the enzymatic core (Bader
et al., 2011; McCutchen-Maloney et al., 2000). However, the pre-
cise molecular mechanism by which PI31 modulates protea-
some activity remains unknown. Previous work also indicated
that PI31 function is regulated in vivo in order to increase 26S
proteasome activity under conditions where maximal proteolytic
activity is required, for example, for the removal of most cellular
proteins during the terminal differentiation of sperm (Bader et al.,
2011). To gain further insight into the regulation of PI31 activity,
we looked for previously unrecognized binding partners of
this protein and identified the ADP-ribosyltransferase tankyrase
(TNKS) as a direct interactor that modulates PI31 activity. TNKS-
mediated ADP-ribosylation of PI31 is necessary for the ability
of this protein to stimulate 26S proteasome function, and the
inhibition of TNKS reduces 26S proteasome activity in both
Drosophila and mammalian cells. TNKS-mediated ADP-ribosy-
lation of PI31 drastically reduces the affinity of this protein for
binding to 20S proteasome a subunits and, thereby, relieves
20S repression by PI31. We also identified the 19S assembly
chaperones dp27 and dS5b as binding partners of PI31. In this
case, ADP-ribosylation of PI31 causes increased binding to
dp27 and dS5b and sequestration of these assembly chaper-
ones from 19S regulatory particles, which promotes 26S assem-
bly. These results reveal an unexpected mechanism of protea-
some regulation and define TNKS inhibitors as a distinct class
of proteasome modulators that may have utility in the clinic.
RESULTS
dTNKS Interacts with DmPI31
Togain insight into themechanismofPI31-mediatedproteasome
regulation, we looked for binding partners of this protein. For this
purpose, we screened aDrosophila embryo complimentary DNA
(cDNA) library by far-western blot analysis using P32-labeled,
HMK-tagged Drosophila PI31 (DmPI31) as a probe. This led to
the identification of Drosophila tankyrase (dTNKS, CG4719) as
a potential interacting protein (data not shown). dTNKS protein
is 44%homologous to human tankyrase 1 and 2 (hTNKS1/2; Fig-
ure S1A available online). Next, we used coimmunoprecipitation
(co-IP) experiments to investigate endogenous interactions
between DmPI31 and dTNKS (Figure 1B). Extracts from wild-
type (WT) embryos were immunoprecipitated with anti-DmPI31,
and blots were probed with an antibody raised against dTNKS
(Figures 1A and S1B). These experiments showed that dTNKS
and DmPI31 form a complex in vivo (Figure 1B). We also coex-
pressed FLAG-tagged dTNKS and HA-tagged DmPI31 in human
embryonic 293 (HEK293) cells to establish a cell-culture system
for subsequent interaction studies (Figure 1C). Again, co-IP ex-
periments with extracts from these cells showed the presence
of a DmPI31:dTNKS complex (Figure 1C).
TNKS belongs to the poly(ADP-ribose) polymerase (PARP)
superfamily (D’Amours et al., 1999; Hsiao and Smith, 2008;
Smith et al., 1998). TNKSs play diverse roles in telomere mainte-
nance, centrosome maturation, Wnt signaling, embryonic devel-
opment, and the pathogenesis of Cherubism (Guettler et al.,
2011; Hsiao and Smith, 2008; Huang et al., 2009; Levaot et al.,
2011). TNKSs recruit and modify target proteins by ADP-ribosy-
lation with the use of their Ankyrin (ANK) and PARP domains (Fig-
ure S1A) (Guettler et al., 2011; Hsiao and Smith, 2008; Huang
et al., 2009; Levaot et al., 2011; Morrone et al., 2012; Smith
et al., 1998). Unlike in mammals, where two isoforms of TNKS
with partially redundant function are present, the Drosophila
genome contains only one TNKS (Chiang et al., 2006, 2008;
Hsiao et al., 2006; Hsiao and Smith, 2008; Yeh et al., 2009). In
order to identify which region of dTNKS is responsible for inter-
action with DmPI31, we generated truncations of dTNKS that
lacked either the ANK or SAM-PARP domains and tested them
for binding to DmPI31 (Figures 1D and 1E). Whereas the SAM-
PARP domains were dispensable for DmPI31 binding, deletion
of the ANK domain in the dTNKSDANK mutant prevented the
formation of the DmPI31:dTNKS complex (Figure 1E). This sug-
gests that dTNKS binds DmPI31 via its ANK domain.A hallmark of TNKS-binding partners is the presence of a
canonical TNKS-binding motif (RxxGxGxE/D) (Guettler et al.,
2011; Hsiao and Smith, 2008; Levaot et al., 2011). DmPI31 con-
tains a good fit to this consensus motif at its N terminus (Fig-
ure 1F). To investigate the functional importance of this motif,
we mutated this sequence by altering two amino acids (RG49/
54AA) and tested binding to dTNKS. The mutant protein was
no longer able to form a complex with dTNKS, indicating that
this motif is required for interaction with dTNKS (Figure 1G,
lane 2). To further characterize the DmPI31-dTNKS interaction,
we generated DmPI31 mutants in which the C-terminal residues,
including the HbYXmotif, were eithermutated or deleted (L210A,
D211K, F241A and P243A, and DHbYX; Figure 1G, lanes 3–7).
Whereas DmPI31D211K and DmPI31P243A mutants retained their
ability to bind dTNKS, DmPI31L210A and DmPI31F241A were un-
able to form a complex with dTNKS (Figure 1G). Furthermore,
deletion of the HbYXmotif in DmPI31 also abrogated the interac-
tion between DmPI31 and dTNKS (Figure 1G, lane 7). This
suggests that dTNKS uses its ANK domain to bind DmPI31
and that both the N-terminal TNKS-binding motif and the C-ter-
minal HbYX domain of DmPI31 are required for interaction with
dTNKS.
dTNKS ADP-Ribosylates DmPI31
TNKSs modulate the activity of target proteins by ADP-ribosyla-
tion (Hsiao and Smith, 2008; Huang et al., 2009; Smith et al.,
1998). Therefore, we investigated whether DmPI31 is a substrate
for dTNKS-mediated ADP-ribosylation. First, we used western
blot analysis with a monoclonal antibody recognizing poly
(ADP-ribosylation) and found that DmPI31 is ADP-ribosylated
in vivo (Figure 2A, lane 3). Next, we performed an in vitro ADP-
ribosylation assay by incubating biotin-labeled NAD+ and His-
DmPI31 along with either FLAG-dTNKSWT or His-dTNKSDPARP
recombinant proteins (Figure 2B). These experiments demon-
strated that dTNKS can directly ADP-ribosylate DmPI31
in vitro, and that this activity requires its PARP domain.
Next, we investigated the significance of TNKS-mediated
ADP-ribosylation for PI31 function and proteasome regulation
in Drosophila and, subsequently, in mammalian cells. For this
purpose, we took advantage of XAV939, a small-molecule inhib-
itor of hTNKS1/2 (Huang et al., 2009). XAV939 was discovered
in a screen for small molecules affecting the Wnt/b-catenin
signaling pathway (Huang et al., 2009). XAV939 is a highly spe-
cific inhibitor of hTNKS1/2 (Kd = 0.09 mM) and has anticancer
effects toward APC-deficient colorectal cancer cells (Huang
et al., 2009). We tested the ability of XAV939 to inhibit dTNKS
and found that it was able to inhibit the auto-ADP-ribosylation
activity of dTNKS, but not PARP (Figures 2C and S2A) (Gibson
and Kraus, 2012; Smith et al., 1998). Therefore, XAV939 is an
effective and specific TNKS inhibitor in Drosophila.
TNKS Regulates Proteasome Activity by
ADP-Ribosylation
Because DmPI31 is required for optimal proteasome activity
in vivo and because dTNKS can posttranslationally modulate
DmPI31, we explored the possibility that the inhibition of TNKS
affects proteasome function. First, we examined the effect of
the TNKS inhibitor XAV939 on 26S proteasome activity inCell 153, 614–627, April 25, 2013 ª2013 Elsevier Inc. 615
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Figure 1. dTNKS, an Interacting Partner of DmPI31
(A) dTNKS antiserum detects purified dTNKS. Purified FLAG-tagged dTNKS is detected in awestern blot with a dTNKSantiserum (lane 3), but not with preimmune
serum (lane 2).
(B) In order to demonstrate that DmPI31 interacts with dTNKS in vivo, 0–2 hr yw (WT) embryo extract was used.
(C) A DmPI31:dTNKS complex can form in mammalian HEK293 cells. The anti-FLAG IP experiments were performed with extracts from HEK293 cells expressing
FLAG-tagged dTNKS along with HA-tagged deIF4A (negative control) or DmPI31.
(D) A schematic representation of WT and mutant dTNKS with their respective domains. Numbers denote amino acid positions.
(E) dTNKS recruits DmPI31 through its ANK domain, as demonstrated via a co-IP experiment using HEK293 cell extracts expressing HA-tagged DmPI31 with
FLAG-tagged dTNKSWT, dTNKSDSAM-PARP, and dTNKSDANK.
(F) Alignments of the TNKS-binding motif with those found in human 3BP2 (Guettler et al., 2011; Levaot et al., 2011) and DmPI31 reveal the presence of a putative
motif in DmPI31. Numbers indicate the position of residues within DmPI31.
(G) dTNKS interacts withmultiple DmPI31 surfaces, such as the putative DmPI31 TNKS-bindingmotif (RG49/54AA) and conservedC-terminal residues (D211 and
P243), including the HbYX domain.
Also see Figure S1.
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Drosophila. Extracts from 0–2 hr yw (WT) embryos were treated
with different compounds and assayed for changes in protea-
some activity (Figure 2E). Treatment with XAV939 significantly
reduced 26S proteasome activity (Figure 2E). Although treat-
ment with XAV939 did not cause complete inhibition of protea-
some activity, as was observed for MG312, the effect was very
similar to inactivation of DmPI31 (Bader et al., 2011). These re-
sults are consistent with a requirement of dTNKS for DmPI31-
mediated proteasome activation. Next, we asked whether
XAV939 could also inhibit proteasome activity in mammalian
cells. For this purpose, we treated HEK293 cell extracts with
XAV939 and measured 26S proteasome activity (Figure 2F).
Again, we found that exposure to this compound decreased pro-
teasome activity. Similar results were obtained with IWR-1,
another TNKS inhibitor that is structurally unrelated to XAV939
(Figure S2B) (Chen et al., 2009; Narwal et al., 2012). This sup-
ports the conclusion that the observed decrease in proteasome
activity is caused by TNKS inhibition and not an unrelated off-
target effect of XAV939. To further corroborate this idea, we
also used RNA interference (RNAi) to target TNKS in both
Drosophila and mammalian cells. First, we expressed RNAi
against dTNKS in the Drosophila retina in a background that
was compromised for proteasome activity (Figure 3). Specif-
ically, expression of temperature-sensitive dominant-negative
mutant for the 20S proteasome b2 and b6 subunits caused a
rough, reduced eye (Belote and Fortier, 2002). Expression of
RNAi against dTNKS further enhanced this phenotype, similar
to what was previously observed for reduction of DmPI31 func-
tion (Figures 3C–3E) (Bader et al., 2011). Therefore, downregula-
tion of dTNKS reduces proteasome activity in vivo. Finally, we
used small interfering RNA (siRNA) to knock down hTNKS1
and hTNKS2 in HEK293 cells (Figure 2D). Again, a significant
reduction of 26S proteasome activities was observed (Fig-
ure 2G). Altogether, these results show that TNKS stimulates
proteasome activity by ADP-ribosylation of PI31.
ADP-Ribosylation Blocks DmPI31 Inhibition of 20S
Proteasomes
Best known for its role in DNA damage, ADP-ribosylation is a
transient posttranslational modification that can drastically alter
the physical properties of target proteins (Chambers et al.,
2012; Gagne´ et al., 2006; Gibson and Kraus, 2012; Wang et al.,
2009). In order to understand the biochemical consequences
of TNKS-mediated ADP-ribosylation of PI31, we investigated
whether this modification affects the binding properties of this
protein. In mammalian cells, PI31 can bind to 20S proteasomes
(McCutchen-Maloney et al., 2000; Zaiss et al., 1999). Likewise,
we found that DmPI31 can bind to 20S proteasomes in
Drosophila (Figure 4A). In particular, DmPI31 bound selectively
to several a subunits (a1, a3, a4, and a6, but not a2 and a5)
(Figure 4A). Next, we used co-IP experiments to evaluate the
role of ADP-ribosylation on the DmPI31:a4 complex. Whereas
unmodified His-PI31 strongly interacted with a4, binding of the
ADP-ribosylated versionwas significantly diminished (Figure 4B).
Consistent with the observed change in DmPI31 affinity for a
subunits, we found that ADP-ribosylation interfered with the
ability of PI31 to inhibit 20S proteasome particles (Figure 4C).
These results demonstrate that ADP-ribosylation blocks thebinding of DmPI31 to 20S subunits and relieves repression of
their proteolytic activity by this protein.
dTNKS and DmPI31 Actively Participates in Proteasome
Assembly
Given that TNKS-mediated ADP-ribosylation of PI31 affects both
20S and 26S proteasome activities, we investigated a possible
role of TNKS and PI31 in 26S proteasome assembly. For this,
we performed Superose 6 gel filtration (fast protein liquid chro-
matography [FPLC]) assays and native gel analyses to study
the effect of TNKS inhibitor XAV939 on proteasome assembly.
Drosophila embryos are an ideal system to study effects on
26S assembly because 65% of proteasomes exist as 20S
particles (Nickell et al., 2007). XAV939 treatment of Drosophila
embryo extracts led to a significant shift in Rpt bands toward
lighter fractions when compared to controls, and it prevented
the formation of 26S proteasomes when analyzed on native
gels (Figures 5A, 5B, S3A, and S3B). This indicates that TNKS
activity promotes 26S proteasome assembly.
Next, we examined the effect of PI31 on 26S proteasome
assembly. Again, we used gel filtration assays to analyze embryo
extracts supplemented with high concentrations of His-DmPI31
recombinant protein (Figure 5C). Again, the addition of His-
DmPI31 caused a significant change in the proteasome architec-
tural landscape by redistributing Rpt3 bands (Figure 5C).
We also observed an increase in Rpt3 monomers (Figure 5C,
top panel; fractions 20–23). These effects were seen for WT
DmPI31, but not for a mutant lacking the HbYX motif (Figure 5C).
The increase in Rpt3monomers can be explained by the ability of
PI31 to bind 19S assembly chaperones (see below) that are
known to stabilize the assembly of both the 19S regulatory par-
ticle and the 26S proteasome (Funakoshi et al., 2009; Kaneko
et al., 2009; Le Tallec et al., 2009; Park et al., 2009; Roelofs
et al., 2009; Saeki et al., 2009). Collectively, these results show
that both TNKS activity and PI31 can modulate 26S proteasome
assembly, and this work suggests a role of PI31 in promoting 19S
stability.
19S Assembly Chaperones Interact with DmPI31
To better understand the role of DmPI31 in proteasome
assembly, we looked for additional DmPI31-binding part-
ners. In the same screen that revealed dTNKS as a DmPI31
interactor, we discovered two other proteasome-associated
proteins—Drosophila p27 (dp27, CG9588) and Drosophila S5b
(dS5b, CG12096). p27 and S5b play a known role as 19S assem-
bly chaperones and, along with Rpn14 and Nas6, bind to 19S
Rpt subunits in order to foster orderly proteasome assembly (Fu-
nakoshi et al., 2009; Kaneko et al., 2009; Le Tallec et al., 2009;
Park et al., 2009; Roelofs et al., 2009; Saeki et al., 2009). As in
yeast and humans, the Drosophila homologs of the 19S assem-
bly chaperones (dp27, 41% homologous; dS5b, 23.3% homolo-
gous; Figures 6B and S5A) are essential genes and are required
for organismal viability (Figures 3F–3L, S4A, and S4B). Immuno-
precipitation (IP) experiments with anti-DmPI31 usingDrosophila
embryo extracts followed by western blot analysis with anti-
dp27 reveal that DmPI31 binds dp27 in vivo (Figures 6A and
S4C). To identify DmPI31 residues involved in dp27 and dS5b-
binding, we used point mutants previously employed to mapCell 153, 614–627, April 25, 2013 ª2013 Elsevier Inc. 617
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Figure 2. dTNKS Posttranslationally Modifies PI31 via ADP-Ribosylation to Regulate 26S Proteasome Activity
(A) DmPI31 is poly(ADP-ribosylated) in vivo. Endogenous DmPI31 ADP-ribosylation was detected with 0–2 hr WT embryo extracts immunoprecipitated with anti-
DmPI31. Eluted proteins were analyzed by western blotting with an anti-poly(ADP-ribose) (PAR) antibody.
(B) dTNKS directly ADP-ribosylates DmPI31 in vitro, and this is dependent on its PARP domain. Samples containing biotin-NAD+, His-DmPI31, and
FLAG-dTNKSWT or His-dTNKSDPARP were analyzed for ADP-ribosylation by western blot analysis. Input proteins were also analyzed by western blotting
(right panel).
(C and D) Tools used to investigate the role of TNKS in 26S proteasome regulation. (C) XAV939 inhibits Drosophila TNKS (dTNKS) in vitro, indicating that the
activity of this drug is conserved across species. (D) siRNAs targeting hTNKS1 and hTNKS2 efficiently knocked down expressions in HEK293 cells. a-tubulin was
used as a loading control.
(E and F) TNKS inhibition by XAV939 reduces proteasome activity in Drosophila embryo (E) and HEK293 cell (F) extracts.
(legend continued on next page)
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Figure 3. dTNKS and dp27 RNAi Enhance
Compromised Proteasome Activity
To test the role of dTNKS and dp27 in modulating
proteasome activity in vivo, we expressed RNAi
against dTNKS (21930, 21932, and 106238; C–E)
and dp27 (28527, 47762, and 47763; F–L) in the
background of dominant-negative temperature-
sensitive mutants (UAS-DTS5 and UAS-DTS7) at
29C. As expected, downregulation of these fac-
tors resulted in a significant enhancement of the
mutant rough reduced eye phenotype (compare B
to C–L) and, in some dp27 RNAi lines, caused
male lethality. These observations are indicative of
reduced proteasome activities in these tissues.
GMR-Gal4 expression caused no discernable eye
defects (A). Orientation of eyes are anterior left and
dorsal up.the DmPI31:dTNKS interaction (Figure 1G). Although mutants
defective for TNKS binding (RG49/54AA) failed to destabilize
the DmPI31:assembly chaperone complex, mutating the con-
served C terminus of DmPI31 (L210, F241, and the HbYX motif)
disrupted these interactions (Figures 6C and S5B). These results
show that the C-terminal HbYXmotif is required for the formation
of a complex between DmPI31 and the assembly chaperones
dp27 and dS5b.
Despite their structural differences, 19S assembly chaperones
use a common mechanism to bind to 19S Rpt subunits (Barrault
et al., 2012; Funakoshi et al., 2009; Lee et al., 2011; Park et al.,
2009; Roelofs et al., 2009; Saeki et al., 2009; Takagi et al.,
2012). Because dp27 and dS5b both interact with DmPI31
C terminus, we performed protein sequence alignments of
dp27, dS5b, and dRpn14. This identified three putative DmPI31-(G) Reduced hTNKS1 and hTNKS2 levels inhibit 26S proteasome activity.
In (E)–(G), data are presented as mean ± SD from three independent experiments. Values obtained for DMSO
(E) *, p = 0.01; (F) *, p = 0.05; (G) *, p = 0.04 and **, p = 0.006. Statistical analysis was performed with a two
Also see Figure S2.
Cell 153, 614–6binding motifs (motifs I–III; Figure 6D). In
order to test the functional relevance of
these motifs, we mutated these sites and
examined the consequences for DmPI31
interaction (Figures 6E and S5C). Point
mutations that replaced key residues in
motifs I and III of dp27 and dS5b (dp27,
E9A and R187A; dS5b, E44A, and
R263A) failed to recruit DmPI31, indicating
a requirement of these motifs for interac-
tion with DmPI31 (Figures 6E and S5C).
These results identify dp27 and dS5b as
interacting partners of DmPI31.
ADP-Ribosylation Promotes 26S
Proteasome Assembly by
Increasing the Affinity of DmPI31
for Assembly Chaperones
Given that ADP-ribosylation of PI31 mod-
ulates 20S proteasome activity by alteringits affinity to a subunits (Figure 4), we wondered if this posttrans-
lational modification may also affect interaction with the 19S
assembly chaperones p27 and S5b. First, to examine this possi-
bility, we performed an anti-FLAG IP experiment using HEK293
cell extracts standardized for FLAG-dp27 and HA-dRpt5
expression followed by rigorous washing and the addition of in-
cremental amounts of in vitro modified DmPI31. The effects of
ADP-ribosylated DmPI31 on the stability of the dp27:dRpt5
and dS5b:dRpt2 complexes were visualized via western blot
(Figures 7A and S6A). Countering its effect on a4 subunit,
ADP-ribosylation considerably increased the ability of DmPI31
to recruit the assembly chaperones when compared to its un-
modified version, sequestering them away from the Rpt base
subunits in a dose-dependent manner (compare Figures 7A
and S6A to Figures 7B and S6B, respectively). These results,(E and F) and control siRNA (G) were set as 100%.
-tailed paired t test.
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Figure 4. ADP-Ribosylation Relieves 20S Inhibition by PI31
(A) DmPI31 interacts with 20S proteasomes via select a subunits; i.e., a1, a3,
a4, and a6.
(B) ADP-ribosylation significantly decreases the affinity of DmPI31 for a4.
FLAG-a4-expressing HEK293 cell extract was incubated with modified
DmPI31 (His-DmPI31ADPR) to test its effect on the a4:DmPI31 complex.
Chemoluminescence was quantitated with ImageQuant LAS 4000 (GE
Healthcare). a4 binding is reported as a relative amount of immunoprecipitated
His-DmPI31 in comparison to the level of input His-DmPI31.
(C) Modification of DmPI31 relieves its inhibitory effect on 20S proteasomes.
Purified bovine 20S proteasomes (0.1 mg) were incubated with His-DmPI31
and His-DmPI31ADPR proteins (2 mg each), and chymotrypsin-like proteasome
activity was measured. Data are presented as mean ± SD from three
independent experiments. The value obtained for 20S proteasome was set as
100%. *, p = 0.04; **, p = 0.6; and ***, p = 0.045. Statistical analysis was per-
formed with a two-tailed paired t test.along with those presented earlier, indicate that ADP-ribosyla-
tion directly modifies DmPI31 affinity for proteasome-associated
proteins.
Evidence for a role of PI31 as an activator of the 26S protea-
some was previously based on the requirement of this protein
for normal proteasome activity in vivo and the ability of this pro-
tein to stimulate 26S proteasome activity in vitro (Bader et al.,
2011). Because modification by ADP-ribosylation differentially
affects the interaction of DmPI31 with different proteasome pro-
teins, we investigated the consequences of PI31modification on
26S proteasome activity in vitro. ADP-ribosylated DmPI31 was
significantly more potent in stimulating the chymotrypsin-like
activity of purified 26S proteasomes in vitro (Figure 7C). Further-
more, when modified DmPI31 was incubated with purified 20S
and 19S particles and analyzed on native gels, we saw that
ADP-ribosylation increased the ability of DmPI31 to promote
de novo 26S assembly in vitro (Figure 7D). Finally, the addition
of ADP-ribosylated DmPI31 to extracts pretreated with XAV939
reversed the inhibitory effect of this compound on 26S protea-
some assembly and was even able to further increase 26S
proteasome assembly (Figure 7E). Also, we found that surplus
PI31 can overcome the effects of XAV939, albeit less efficiently
than its modified counterpart. This is consistent with our obser-
vation that unmodified PI31 can bind and sequester 19S assem-
bly chaperones (Figure S6B). Altogether, our data show that
dTNKS-dependent ADP-ribosylation of DmPI31 stimulates 26S
proteasome activity by promoting 26S assembly.
DISCUSSION
It is becoming increasingly clear that the proteasome, often
thought to be a constitutively active protease complex, is
dynamically regulated in order to meet the changing proteolytic
needs of a cell (Demartino and Gillette, 2007; Glickman and
Ciechanover, 2002; Hershko and Ciechanover, 1998). Although
the polyubiquitination of substrates is central in selecting spe-
cific proteins for degradation, additional mechanisms must exist
to account for the plasticity of proteasome activity (Crosas
et al., 2006; Demartino and Gillette, 2007; Hanna et al., 2007;
Kurucz et al., 2002; Murata et al., 2009; Peth et al., 2009,
2013, 2010; Princiotta et al., 2001). Here, we identified TNKS
as a regulator of proteasome activity in both Drosophila and
mammalian cells. Specifically, we show that TNKS-mediated
ADP-ribosylation of PI31 alters the affinity of this protein for
20S proteasome a subunits and 19S assembly chaperones
and, thereby, stimulates 26S proteasome assembly. Our results
support a model in which TNKS activates an evolutionarily
conserved proteasome-regulatory protein, PI31, by ADP-ribo-
sylation (Figure 7F). PI31 is physiologically required for optimal
26S proteasome activity in vivo, and inactivation of the corre-
sponding gene in Drosophila causes reduced protein break-
down and organismal lethality (Bader et al., 2011). Inhibition of
TNKS by either RNAi or with a specific small-molecule inhibitor,
XAV939, blocked ADP-ribosylation of PI31 and impaired 26S
proteasome activity in a manner similar to the inactivation of
PI31. It was suggested that PI31 may act as a modulator of pro-
teasome assembly by reversibly associating with 20S protea-
some (Besche et al., 2009a; McCutchen-Maloney et al., 2000;620 Cell 153, 614–627, April 25, 2013 ª2013 Elsevier Inc.
AB C
Figure 5. TNKS and PI31 Regulate Proteasome Assembly
(A) Inhibition of dTNKS by XAV939 led to a drastic shift of the proteasome profile to ‘‘lighter’’ fractions, indicative of reduced amounts of 26S particles. To assess
the effect of TNKS activity on 26S assembly, we subjected embryo extracts treated with XAV939 to Superose 6 gel filtration chromatography.
(B) TNKS inhibition severely affects 26S proteasome assembly. The effect of XAV939 on proteasome assembly in embryo extracts was assessed by native gel
analysis.
(C) Similar to XAV939, surplus DmPI31 dramatically affected proteasome assembly. Furthermore, it also caused an increase in levels of Rpt3monomers (fractions
20–23), as visualized by gel filtration chromatography.
In (A)–(C), western blot analyses were performed to detect the presence of the proteasomal subunits Rpt3 (a 19S component that can be used to identify 26S) and
a7 (to identify 20S). In (A) and (C), arrows and arrowheads indicate the position of proteasome components (red arrows; 26S, 19S, and 20S) and standards (black
arrowheads; 660 kDa Thyroglobulin and 66.5 kDa BSA), respectively.
Also see Figure S3.Tai et al., 2010; Tanahashi et al., 1999; Zaiss et al., 1999, 2002).
In support of this idea, we show that PI31 modification by TNKS
facilitates the assembly of the 26S proteasome by acting at two
crucial stages (Figure 7F). First, TNKS-mediated ADP-ribosyla-
tion decreases the affinity of PI31 for a4 subunits of the 20S par-
ticle. This dislodges PI31 from 20S proteasomes and prevents
PI31 from inhibiting 20S activity. Once free, modified PI31 com-
petes with Rpt subunits to sequester the assembly chaperones
p27 and S5b away from 19S regulatory particles, thereby pro-
moting the capping of 20S with 19S particles. This is consistentwith previous observations where the overexpression of p27,
S5b, and Rpn14 (PAAF1) proteins negatively affected protea-
some assembly (Kaneko et al., 2009; Lassot et al., 2007; Park
et al., 2005; Shim et al., 2012). By acting on both 20S particles
and assembly chaperones, PI31 appears to function as a central
regulator of 26S proteasome assembly (Figure 7F). Significantly,
this process can be disrupted with existing small-molecule
compounds; TNKS inhibitors represent a distinct class of com-
pounds that inhibit 26S activity by interfering with proteasome
assembly.Cell 153, 614–627, April 25, 2013 ª2013 Elsevier Inc. 621
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Figure 6. The 19S Assembly Chaperone dp27 Interacts with DmPI31
(A) Endogenous dp27:DmPI31 interaction was detected in an anti-DmPI31 IP experiment using embryo extracts.
(B) Sequence alignment of p27 from human (hp27) and D. melanogaster (dp27). dp27 is 41% homologous to hp27. Identical amino acids are colored in violet and
the DmPI31-binding motifs (I-III; refer to D) are denoted in green.
(C) DmPI31 recruits dp27 via its C-terminal residues; i.e., L210, F241, and the HbYX domain. Similar observations were made for TNKS (Figure 1G).
(D) dp27, dS5b, and dRpn14 protein sequence alignments reveal three putative DmPI31-binding motifs (I–III) with unique conserved residues (shown in red
boxes). Numbers denote N-terminal end amino acid positions of each motif in respective proteins.
(E) Multiple dp27 surfaces (motifs I [E9A] and III [R187A]) make contact with DmPI31 to stabilize the complex.
Also see Figures S4 and S5.PI31 is required for normal proteasome activity in vivo, and it
can also stimulate the activity of purified 26S proteasome
in vitro (Bader et al., 2011). In order to explain the latter finding,
we invoke the possibility that purified 26S proteasomes used in
these experiments contain associated proteins, including 19S
assembly chaperones. This is consistent with observations
showing p27 and S5b in associationwith the purified 26S protea-
some (Besche et al., 2009a; Deveraux et al., 1995; Gomes et al.,
2006; Tai et al., 2010; Watanabe et al., 1998). Furthermore, un-
modified PI31 can still bind to assembly chaperones, albeit
with much lower efficiency (Figure S6B). Altogether, these re-
sults suggest that PI31 stimulates proteasome activity in vitro
by increasing 26S particles.
The rate of intracellular protein degradation is dramatically
affected by various signals, including the metabolic state of the
cell (Glickman and Ciechanover, 2002). For example, caloric re-
striction can cause a severe reduction of skeletal muscles, and
humans loose a large fraction of their muscle mass during aging.
Although this appears to have evolved as a protective mecha-622 Cell 153, 614–627, April 25, 2013 ª2013 Elsevier Inc.nism to cope with food shortage, muscle atrophy can be a highly
debilitating process that also occurs in various diseases, such as
cancer cachexia, AIDS, renal failure, and neurodegenerative dis-
eases. In all these cases, proteasome activity is responsible for
protein breakdown and cellular atrophy, but a direct connection
between metabolism and proteasome activity has not yet been
established. Given that NAD+ is the source of the ADP-ribose
group, proteasome regulation by TNKS provides a potential
link between cell metabolism and the regulation of protein degra-
dation (Gibson and Kraus, 2012). Because ADP-ribosylation has
a very short half-life (1–2 min), it is ideally suited to rapidly signal
transient changes in cell physiology (Chambers et al., 2012;
Gibson and Kraus, 2012; Lindahl et al., 1995; Wang et al.,
2009). We speculate that TNKS-mediated activation of PI31
may serve to stimulate proteasome activity when cells need to
dynamically boost their proteolytic capacity in order to meet
changing demands, such as during cellular remodeling, upon
stress conditions, and during caloric restriction. It is also
possible that the activation of PI31 occurs only in specific
A B
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Figure 7. ADP-Ribosylation Increases DmPI31 Affinity for dp27 to Regulate Proteasome Assembly and a Model for Proteasome Regulation
by ADP-Ribosylation
(A and B) ADP-ribosylation increased the affinity of DmPI31 for dp27, allowing it to compete with dRpt5 for chaperones in a dose-dependent manner. Anti-FLAG
IP with HEK293 cell extracts standardized for FLAG-dp27 and HA-dRpt5 expressions were supplemented with in vitro modified (A) and unmodified (B) DmPI31 in
order to assess their ability to compete with dRpt5 for dp27.
(C) ADP-ribosylated DmPI31 activated 26S proteasome activity in vitro to levels beyond those seen for its unmodified control. Purified bovine 26S proteasome
(0.1 mg) was incubated with His-DmPI31, His-DmPI31DHbYX, and His-DmPI31ADPR (2 mg each), and chymotrypsin-like proteasome activity was assayed. Data are
presented as mean ± SD from three independent experiments. The value obtained for 26S + His-DmPI31WT was set as 100%. *, p = 0.46; **, p = 0.007. Statistical
analysis was performed with a two-tailed paired t test.
(legend continued on next page)
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subcellular compartments; for example, within the nucleus, in
specific neuronal processes undergoing pruning, or in synapses
during remodeling. In this way, it may be possible to locally fine-
tune the assembly and activity of 26S proteasomes to meet a
cell’s changing needs for controlled proteolysis.
The proteasome is a validated drug target for cancer therapy
and bortezomib (VELCADE), which inhibits the chymotrypsin-
like activity of the proteasome, is approved in the U.S. for the
treatment of multiple myeloma and mantle cell lymphoma (Gold-
berg, 2012; Kisselev et al., 2012; Raab et al., 2009). Problems
associated with bortezomib include notable side effects, such
as peripheral neuropathy and drug resistance (Goldberg, 2012;
Kisselev et al., 2012; Raab et al., 2009). Therefore, drugs that
inhibit proteasome activity by a separate mechanism may have
considerable clinical value. Our findings suggest that TNKS
inhibitors, such as XAV939 and IWR-1, may be useful for the
treatment of multiple myeloma, mantle cell lymphoma, and other
cancers sensitive to proteasome inhibition. Consistent with this
idea, we have preliminary evidence that XAV939 can block the
growth of multiple myeloma cells (Figure S6C). Besides inhibiting
proteasome activity by an entirely distinct mechanism, TNKS
inhibitors are expected to only block maximal activation of 26S
function, but not the basal activity of the proteasome, and,
hence, may have fewer side effects (Figure 7F). Interestingly,
XAV939 has already been shown to be effective against colo-
rectal cancer cells and is thought to antagonize Wnt signaling
by preventing the degradation of axin (Huang et al., 2009).
However, the contribution of proteasome inhibition in this para-
digm has not yet been determined. Proteasome regulation by
tankyrase-mediated ADP-ribosylation provides an unexpected
mechanism for the regulation of protein degradation that can
be targeted with small-molecule inhibitors.EXPERIMENTAL PROCEDURES
Recombinant Protein Purification and Far-Western Screening of the
cDNA library
For the purification of His-DmPI31, His-DmPI31DHbYX, His-HMK-DmPI31, and
His-dTNKSDPARP fusion proteins, E.coli BL21 (Invitrogen) was transformed
with the pET28-His-DmPI31, pET28-His-DmPI31DHbYX, pET101-His-HMK-
DmPI31, and pET101-His-dTNKSDPARP constructs. After a 2 hr induction at
37C with 0.1 mM IPTG, the fusion proteins were purified on a TALON Metal
Affinity Resin (BD Biosciences) according to the manufacturer’s instructions.
For the purification of FLAG-dTNKS and FLAG-dPARP, HEK293 cell extracts(D) DmPI31 modification promotes de novo assembly of the 26S proteasome. Pur
His-DmPI31, His-DmPI31DHbYX, and His-DmPI31ADPR (5 mg each) in the presenc
modified DmPI31 on proteasome assembly.
(E) Modified DmPI31 rescues XAV939-induced defects in 26S proteasome assem
treated with the TNKS-inhibitor were supplemented with 5 mg of respective prote
In (D) and (E), native gels were analyzed via western blot with anti-Rpt3 (for 26
quantitated with ImageQuant LAS 4000 (GE Healthcare). 26S proteasome assem
(F) Amodel for proteasome regulation by ADP-ribosylation. PI31 is a conserved pro
in vivo and organismal viability (Bader et al., 2011). ADP-ribosylation of PI31 by TN
to increased proteolytic activity of the 26S proteasome by promoting its assem
proteasome a subunits and dislodges PI31 from 20S particles. On the other hand
and dS5b and, thereby, sequesters them away from 19S regulatory particles. Alto
of intracellular proteins. Inhibition of TNKS by small-molecule compounds, such as
TNKS inhibitors represent a distinct class of proteasome inhibitors that target th
Also see Figure S6.
624 Cell 153, 614–627, April 25, 2013 ª2013 Elsevier Inc.expressing the pcDNA3.2-FLAG-dTNKS and pcDNA3.2-FLAG-dPARP con-
structs were incubated with ANTI- FLAG M2 Affinity Gel (Sigma-Aldrich) for
3 hr and purified with FLAG peptide (Sigma-Aldrich) according to themanufac-
turer’s instructions. Far-western screening of the cDNA library was performed
as previously described (Pause et al., 1994) with theDrosophila l cDNA Library
(Stratagene).
Cell Culture and Growth Assay
Cationic lipid reagent (20 ml of Lipofectamine 2000; Invitrogen) was diluted in
serum-free media (Opti-MEM; Invitrogen) for transfection in HEK293 cells
(100 mm dish). Following a 5 hr incubation, the medium was replaced with
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10%
fetal bovine serum (FBS). Transfected cells were harvested in PBS 48 hr
following the addition of serum-containing media. The cells were then lysed
by repeated freeze/thaw cycles in 600 ml of lysis buffer (20 mM HEPES-KOH
[pH 7.6], 200 mM KCl, 0.5mM EDTA, 10% glycerol, 1% Triton X-100 and pro-
tease inhibitor cocktail [Complete; Roche]) that contained RNase A (50 mg/ml;
Sigma-Aldrich). Cell debris was pelleted by centrifugation, and the protein
concentration in the supernatant was determined with the Bio-Rad assay.
The siRNAs purchased from Invitrogen (sequences shown in Table S1) were
transfected in HEK293 cells at a final concentration of 50 nM/100 mm dishes
with the use of Lipofectamine 2000. Effects of drug treatment on U266multiple
myeloma cell growth were performed with 0.1 mM of bortezomib and 5 mM
of XAV939 in low-FBS (0.5%) RPMI media and 96-well plates seeded with
8,000 cells per well. Samples were assayed for growth and viability with
PrestoBlue Cell Viability Reagent (Invitrogen) in a Spectramax M2 reader
(Molecular Devices) per the manufacturer’s instructions.
Coimmunoprecipitation
For co-IP, HEK293 cell extract (200 ml; 6–10mg/ml) was brought up to 1 ml with
the lysis buffer and precleared for 1 hr at 4Cwith 25 ml of Protein A Sepharose
(GE Healthcare). The supernatant was immunoprecipitated for 1 hr at 4C with
25 ml of ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich). The resin was washed
twicewith lysis buffer and oncewith lysis buffer containing 300mMKCl. Immu-
noprecipitates were eluted in 3X red sample buffer (New England Biolabs). For
anti-HA and anti-DmPI31 IPs, 25 ml of Protein A Sepharose was preincubated
for 2 hr with anti-HA (3 ml) and anti-DmPI31 (5 ml). The resins were washed three
times with the lysis buffer prior to IP, as described above. Embryo extracts
were used at a concentration of 5 mg/ml.
Proteasome Activity Assay
For proteasome activity assays, 50 mg of 0–2 hr WT embryo or 3 mg of HEK293
cell extracts in PIPES buffer (50 mM PIPES, 1 mM MgCl2, 50 mM NaCl, 2 mM
EGTA, and 2 mM ATP) were programmed with 1% DMSO (Sigma-Aldrich),
5 mM MG132 (Calbiochem), 2 mM XAV939 (Sigma-Aldrich), and 2 mM IWR-1
(Sigma-Aldrich), respectively, and incubated for 20 min at room temperature.
Samples were assayed for proteasome activity with the Proteasome-Glo
Chymotrypsin-like Cell-Based Assay (Promega) in a Spectramax M2 reader
(Molecular Devices). To assess the effect of ADP-ribosylation on 20S and
the 26S proteasome activities, we programmed purified bovine 20S and 26Sified bovine 19S and 20S proteasome particles (1 mg each) were incubated with
e of ATP, followed by native gel analysis for the assessment of the effect of
bly to a greater extent than its unmodified control. 200 mg of embryo extracts
ins followed by native gel analysis.
S proteasome) and anti-a7 (for 20S proteasome). Chemoluminescence was
bly status is reported as the relative intensity of Rpt3 bands.
teasome-regulatory protein that is required for normal 26S proteasome activity
KS, which transfers the ADP-ribose group fromNAD+, activates PI31 and leads
bly. Specifically, ADP-ribosylation of PI31 causes decreased affinity for 20S
, ADP-ribosylation increases binding of PI31 to the assembly chaperones dp27
gether, this promotes 26S proteasome assembly and facilitates the breakdown
XAV939, blocks this process and reduces 26S proteasome activity. Therefore,
e assembly of 26S proteasomes.
proteasomes (0.1 mg; UBPBio) in PIPES buffer + 2 mM ATP were programmed
with 2 mg of His-DmPI31WT, His-DmPI31DHbYX, and His-DmPI31ADPR, and
incubated for 20 min at room temperature. Samples were assayed for protea-
some activity as described above.
Gel Filtration Assay
For gel filtration assays, 2 mg of 0–2 hr WT embryo extracts prepared with the
PIPES buffer + 2 mM ATP were centrifuged twice at 14,000 rpm for 20 min at
4C prior to being treated with 50 mg His-DmPI31, 50 mg His-DmPI31DHbYX,
50 mg His-DmPI31ADP-ribosylation, 1% DMSO, 5 mM MG132, 2 mM XAV939,
and 2 mM Olaparib (LC Laboratories) for 30 min. Subsequently, gel filtration
assay was performed using Superose 6 10/300GL FPLC column (GE Health-
care). We collected 500 ml fractions using a 0.250 ml/min flow rate. Purified
bovine 19S, 20S, and 26S proteasomes (UBPBio), thyroglobulin, and BSA
were used as standards.
In Vitro ADP-Ribosylation Assay and Purification of His-DmPI31ADPR
Recombinant His-DmPI31 (1 mg), FLAG-dTNKS (0.1 mg), and His-dTNKSDPARP
(0.1 mg), along with biotin-NAD+ (3.5 mM; Trevigen) were incubated for 5 hr
at 37C and subjected to SDS-PAGE followed by western blotting with
Streptavidin HRP (Thermo Scientific; 1:10,000). The effects of XAV939 on
dTNKS and dPARP were assessed by incubating biotin-NAD+ and FLAG-
dTNKS or FLAG-dPARP mixtures with either 0.1% DMSO or 0.1 mM
XAV939. For the purification of His-DmPI31ADPR protein, in vitro ADP-ribosyla-
tion of recombinant His-DmPI31 protein was performed as above. This was
followed by serial purifications with the use of TALON Metal Affinity Resin
(Clontech Laboratories) and SoftLink Soft Release Avidin Resin (Promega)
per the manufactures’ instructions.
Native Gel Analysis
To analyze proteasome assembly status, we resolved 200 mg of embryo ex-
tracts exposed to different experimental conditions + 2 mM ATP using 5%
Tris-HCl acrylamide gels (Bio-Rad) under nondenaturing conditions and trans-
ferred the extracts onto a 0.22 mm PVDF membrane. Western blot analyses
with the specific antibodies were performed as described above. Concentra-
tions of various reagents were 1%DMSO, 5 mMMG132, 2 mMXAV939, purified
bovine 19S and 20S (1 mg), and 5 mg of His-DmPI31WT, His-DmPI31DHbYX, and
His-DmPI31ADPR proteins.
Fly Strains
UAS-DTS5 and UAS-DTS7 lines were obtained from J. Belote, dTNKS (21930,
21932, and 106238), dp27 (28527, 47762, and 47763), dS5b (104492), and
dRpn14 (32697 and 32698) RNAi lines were obtained from the Vienna
Drosophila RNAi Center and the Bloomington Drosophila Stock Center.
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Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at http://dx.
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